[8] Some of Mankind Pharma's consumer healthcare brands are the largest-selling in their respective categories, including Manforce in condoms,[10] Prega News in pregnancy test kits,[11] and Unwanted-72 in emergency contraception.

[23] In 2019, Mankind became the first Indian company and second only in the world to develop and launch Dydrogesterone, a drug used in high-risk pregnancies and infertility by the brand name Dydroboon.

[29] In April 2023, Mankind Pharma launched its initial public offering (IPO), with existing investors selling ₹4,326 crore (US$500 million) worth of shares.

[30] In 2024, Mankind Pharma acquired a 100% stake in Bharat Serums and Vaccines (BSV) from private equity firm Advent International for an enterprise value of ₹13,630 crore (US$1.6 billion).

[31] As per Forbes list of India’s 100 richest tycoons, dated 9 October 2024, Ramesh and Rajeev Juneja & family are ranked 42nd with a net worth of $7 billion.